Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group
Jean‐Pierre Pignon, Hélène Tribodet, Giorgio V. Scagliotti et al. · Journal of Clinical Oncology · 2008
PURPOSE: Several recent trials have shown a significant overall survival (OS) benefit from postoperative cisplatin-based chemotherapy in patients with non-small-cell lung cancer (NSCLC). The aim of the Lung Adjuvant Cisplatin Evaluation was to identify treatment options associated with a higher benefit or groups of patients who particularly benefit from postoperative chemotherapy. PATIENTS AND METHODS: Individual patient data were collected and pooled from the five largest trials (4,584 patients) of cisplatin-based chemotherapy in completely resected patients that were conducted after the 1995 NSCLC meta-analysis. The interactions between patient subgroups or treatment types and chemotherapy effect on OS were analyzed using hazard ratios (HRs) and log-rank tests stratified by trial. RESULTS: With a median follow-up time of 5.2 years, the overall HR of death was 0.89 (95% CI, 0.82 to 0.96; P = .005), corresponding to a 5-year absolute benefit of 5.4% from chemotherapy. There was no heterogeneity of chemotherapy effect among trials. The benefit varied with stage (test for trend, P = .04; HR for stage IA = 1.40; 95% CI, 0.95 to 2.06; HR for stage IB = 0.93; 95% CI, 0.78 to 1.10; HR for stage II = 0.83; 95% CI, 0.73 to 0.95; and HR for stage III = 0.83; 95% CI, 0.72 to 0.94). The effect of chemotherapy did not vary significantly (test for interaction, P = .11) with the associated drugs, including vinorelbine (HR = 0.80; 95% CI, 0.70 to 0.91), etoposide or vinca alkaloid (HR = 0.92; 95% CI, 0.80 to 1.07), or other (HR = 0.97; 95% CI, 0.84 to 1.13). Chemotherapy effect was higher in patients with better performance status. There was no interaction between chemotherapy effect and sex, age, histology, type of surgery, planned radiotherapy, or planned total dose of cisplatin. CONCLUSION: Postoperative cisplatin-based chemotherapy significantly improves survival in patients with NSCLC.
Cited by 2,637 works. doi:10.1200/jco.2007.13.9030 Open-access PDF
Authors
- Jean‐Pierre Pignon
- Hélène Tribodet
- Giorgio V. Scagliotti
- Jean-Yves Douillard
- Frances A. Shepherd
- Richard J. Stephens
- Ariane Dunant
- Valter Torri
- Rafael Rosell
- Lesley Seymour
- Stephen G Spiro
- Estelle Rolland
- Roldano Fossati
- Delphine Aubert
- Keyue Ding
- David A. Waller
- Thierry Le Chevalier
References
- Quantifying heterogeneity in a meta‐analysis
- Beta blockade during and after myocardial infarction: An overview of the randomized trials
- Cancer incidence, mortality and prevalence worldwide
- Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy
- Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials
- Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials
- Effects of Radiotherapy and Surgery in Early Breast Cancer — An Overview of the Randomized Trials
- A note on quantifying follow-up in studies of failure time
- Effects of Radiotherapy and Surgery in Early Breast Cancer — An Overview of the Randomized Trials
- Cisplatin-Based Adjuvant Chemotherapy in Patients with Completely Resected Non–Small-Cell Lung Cancer